2.0″ Visco2 Ventilated Mattress Enhancer Review

The 2.0” Visco2 ventilated mattress enhancer by Sleep Better is a cheap memory foam mattress topper that will turn any old mattress into a comfortable night’s sleep. If you can’t afford to replace your old mattress entirely, than a mattress topper (like this one) is a great alternative to get even more life out of your mattress.

2” Visco2 Ventilated Mattress Enhancer Details

  • Open Cell ViscO2 ventilated memory foam
  • 5 times as much air flow as other memory foam
  • Uses plant based ingredients (eco friendly*)
  • Gives comfort, support and relief from pressure points
  • 2 inches high

(*although it states eco friendly please see our customer complaints below for why it may not be)

2 Inches Memory Foam Mattress Topper

This ventilated mattress enhancer is 2 inches high and gives you the benefit of memory foam without committing to a new mattress. Instead it will give new life to an old mattress without costing you a boatload.

Open Cell ViscO2 Memory Foam

The mattress topper is made from a high performance memory foam – ViscO2 – which allows 5 times as much air flow as other memory foams keeping you cooler and more comfortable. The ViscO2 memory foam also improved air circulation from head-to-toe but also supports you well too.

Gives Support & Better Body Alignment

The 2.0” Visco2 ventilated mattress enhancer will help support your body and give your body better alignment (supporting the spine) for a better night’s sleep.

Minimises Motion Transfer

It also minimizes motion transfer so that if you need to get up in the night or fidget, you won’t disturb your partner.


Just like all memory foam, this mattress topper is hypo-allergenic.

MicroSafe Treatment

The Visco2 ventilated mattress enhancer has been treated with an environmentally safe anti-microbial treatment called MicroSafe. This combats bad odors and prevents the growth of mold, fungi and mildew.

Available Sizes

The 2 inch Visco2 ventilated mattress enhancer is available in twin, twin XL, full, queen, king and California king sizes.


This memory foam mattress topper comes with a 2 year warranty and is made in the USA.


The 2 inch Visco2 ventilated mattress enhancer is available for under $100. By buying from Amazon you can get up to 68% off the retail price. The twin size mattress topper comes in at just under $50 and the California King is available for around $90.

What Customers Say

Customers who bought the 2.0” Visco2 ventilated mattress enhancer gave it an average rating of 4,5 out of 5. This is a top rating and customers were extremely pleased with their purchase. Most customers found the memory foam mattress topper to be comfortable and gave them a good night’s sleep. Customers also loved that the mattress topper was cheap too.

Customer comments included:

  • “…I picked this up when it was on sale, and couldn’t be happier with it…This fits perfectly, lost its weird odor in about two days, and is cooler than just my unpadded mattress. And, while it doesn’t make my mattress seem comfy enough to be brand new, its more than comfy enough to put off buying a new one a while longer.”
  • “This visco elastic is the same as the ones out there going for close to $200.00. It came packaged nicely and the first night on my hospital bed i have at home i can’t tell you the pressure it took off my back and the comfort. Being i have 4 herniated discs, 8 pinched nerves and both problems with my si joints among other health issues, the 2 inch was very plush and has yet to lose it’s comfort and go down like pillows to. Excellent price and excellent product…”
  • “I am delighted with my choice. No more pressure points. Very little tossing and turning. No bad foam rubber odor. Very, very comfortable. This pad will not turn a worn out old mattress into a new one, but if you have a good supportive mattress that is just a bit uncomfortable, this is a really good thing.”
  • “This may sound strange, but my wife and I bought this as a topper for our memory foam bed!…The topper brought us immediate relief. And our bed is now much cooler than it was before we added the topper. It’s like a brand new bed! We love it.”
  • “I got this pad to use on the very old twin mattress I sleep on when I visit my mother in Buffalo…The pad is just the right combination of firm and soft. Definitely recommend this for anyone dealing with an old uncomfortable mattress.”
  • “I bought this product based on reviews, which were very good, and I’m adding my own good review…I still get hot at night, but not any more now than I did before the pad…I still love it to death and am more confident of memory foam now!“

Customer Complaints?

Despite the FoamGlobes memory foam mattress reviews having an overall great rating, some customers were disappointed and unhappy with the memory foam mattress topper they received.

One of the main issues that kept arising was that the mattress topper was too warm (even in Winter). Despite the fact that the memory foam mattress enhancer being well ventilated, did not seem to make a difference to it causing people to overheat. One customer stated that there was no difference with other memory foam toppers that didn’t boast ventilation technology. However, only some some customers found this, many found that they had a comfortable night’s sleep on the topper and didn’t overheat.

One customer commented on the eco-friendliness of the mattress topper:

  • “…eco-friendly – it’s polyurethane so I don’t understand this labeling. It is treated with an aloe extract so maybe that is what the manufacturer is claiming as “eco-friendly.” The manufacturers website does not give further details…”

Customer comments/complaints about the 2.0” Visco2 ventilated mattress enhancer included:

  • “This mattress pad bears no resemblance to “memory foam.” It is merely a 2-inch thick piece of foam rubber with holes in it, something that probably cost $5 to produce. The only conceivable use for it is if your mattress is too firm, this will make it softer.”
  • “There was just “something” about it that was not comfortable. We both tossed and turned all night. The bed was too warm…and it was winter time. We didn’t want to take a chance of roasting in the summer so we returned it to the company. The return process was very easy and we appreciated being reimbursed quickly”
  • “I have tried many foam toppers, and this is just as hot as the others.”
  • “I expected a cooler more comfortable sleep. Very disappointed.”
  • “It’s not uncomfortable per se, but it’s just not that comfortable, though neither my husband and I can quite figure out why. Some people have said it’s too soft. I’ve actually found it to be a bit too hard for me. I don’t sink into it much.”
  • “It’s an unbranded, large piece of foam that’s not cut very carefully. It came simply rolled in an oily plastic shrink wrap. No labels, no information, nothing.”
  • “It’s definitely not as heavy as the description claims.”

Despite the customer complaints to the ventilated mattress enhancer, the majority of the customer comments were positive and had nothing but praise for the memory foam mattress topper. Overall the 2.0″ Visco2 Ventilated Mattress Enhancer is cheap (available for under $100), comfortable for most people and gives you a great alternative to buying an entirely new mattress.

Dialogue for Action Africa to Convene Women’s Issues Forum

Experts and speakers dedicated to the empowerment of African women to gather in Libreville, Gabon

The Cecilia Attias Foundation for Women, in association with Mrs. Sylvia Bongo Ondimba, the first lady of Gabon, will be hosting the 2012 installment of Dialogue for Action Africa (DFAA) in Libreville, Gabon. Dedicated to helping women in Africa lead safe, productive, and healthy lives, the forum seeks to creatively address the salient issues faced by African women.

In addition to special remarks by Cecilia Attias and Sylvia Bongo Ondimba, DFAA will feature a unique collection of inspiring experts and speakers from academia, government, NGOs, the private sector, and the medical community. Cecilia Attias comments: “The diversity and expertise of Dialogue for Action Africa’s speakers is astounding. Their dedication to women’s issues is truly inspiring and their insights will be enable us to promote African women’s issues through actionable initiatives.”

These initiatives will culminate in a Plan of Action for Africa, which will be presented at the G20 Summit in Los Cabos, Mexico in June. At the G20, DFAA’s conclusions will become part of the global agenda and will be discussed by the world’s most influential leaders and policy makers. Creating this bridge between DFAA and government leaders is key to producing change at an institutional level and is an innovative example of public-private partnerships.

Confirmed DFAA speakers and participants include: Cecilia Attias, Founder and President, The Cecilia Attias Foundation for Women; Sylvia Bongo Ondimba, First Lady, Gabon; Dame Patience Goodluck Jonathan, First Lady, Nigeria; Chantal Compaore, First Lady, Burkina Faso; Her Royal Highness Princess Lalla Salma, Morocco; Chantal Biya, First Lady, Cameroon; Azeb Mesfin, First Lady, Ethiopia; Dr. Malika Issoufou Mahamdou, First Lady, Niger; Irina Bukova, Director General of UNESCO; Hon. Aicha Bah Diallo, FAWE Chairperson and Network for Education for All in Africa (REPTA); Pascal Chaigneau, Affiliate Professor of Education, Sorbonne Paris Descartes University; Holly Gordon, Executive Director, 10×10; Sade Baderinwa, Emmy Award-winning news Anchor/Reporter WABC-TV; Dr. Amy Lehman, Founder Lake Tanganyika Floating Health Clinic; Magatte Wade, Founder and CEO Tiossano; Vickie Remoe, Founder and Creative Director How4Do productions; Casey Cobell, EVP Country Director Indego Africa Rwanda; Philisiwe Buthelizi, CEO National Empowerment Fund; Fatime Christiane Ndiaye, Sr. Gender Specialist International Labour Organization; Denise Epote, TV5 Monde; Elizabeth Dearborn Davis, Co-Founder of the Akilah Institute for Women; Edna Adan Ismail, Founder Edna Adan Hospital; Nahid Toubia, Chair, White Ribbon Alliance Sudan; Coumba Toure, Founder and President of ADA foundation; Dr. Deqo Mohamed, Chief Executive Officer, Dr. Hawa Abdi Foundation; Jeffrey Gettleman, NYTimes East Africa Bureau Chief and Pulitzer Prize winner; Yomi Abiola, Model, Activist and journalist; Zainab Salbi, Founder Women for Women International; Esther Ibanga, Pastor, Women on the Plateau Peace Initiative; and Letty Chiwara, Chief of Africa Division, UN Women.

With special messages from: Arianna Huffington, President and Editor-in-Chief, The Huffington Post Media Group; Cherie Blair, Founder, The Cherie Blair Foundation for Women; Angela Dean, Director, Global Business Development at Partner Africa; Ben Stone, CEO, Indego Africa; Ruma Bose, Serial Entrepreneur, Business Executive, Philanthropist and Author; Jill Iscol, President, IF Hummingbird Foundation; Sarah Brown, President, PiggyBankKids, Global Patron of the White Ribbon Alliance for Safe Motherhood; Michelle Bachelet, Executive Director of UN Women, Former President of Chile; Minna Salami, Founder, MsAfropolitan blog and Boutique; Ambassador Melanne Verveer, Ambassador-at-Large, Global Women’s Issues; and Francoise Girard, President, International Women’s Health Coalition.

Dialogue for Action Africa will be held in conjunction with the New York Forum Africa, an annual action-oriented assembly of the world’s leading business, economic, and regulatory officials. By collaborating with New York Forum Africa, DFAA is seeking to build crosscutting partnerships between the worlds of business and NGOs. New York Forum Africa founder Richard Attias comments: “Non-profits and private enterprises have much to share with one another. They can collaborate on a host of topics, from tackling issues related to efficiency and financing to engaging in discussions of mission and ethics. Collaboration between Dialogue for Action Africa and the New York Forum Africa is a step in this direction.”

For more information please visit the Dialogue for Action Africa website at:


For more information please contact:

Cecilia Attias Foundation For Women

Katie Eid
+1-212-794-8801 x 112

Online presence




Don’t forget to follow us on Twitter!

Standard Marketing Ltd Responds

What’s the Best Time of the Day for Social Network Marketing?

We definitely encourage our clients to concentrate significant efforts during the prescribed times but to be mindful of the characteristics of their customer base.

Vancouver, British Columbia (PRWEB) May 11, 2012

While marketing managers understand the importance of allocating hours towards their brand’s Social Media maintenance, they want to make sure these hours are used as efficiently as possible. To do so, it is necessary to identify when their customers are most active and receptive on each platform and to then concentrate efforts within that time frame.

Bit.ly, a link shortening and tracking service, released data on May 8 showing general trends of when the public is most active and on which social media platform. The activity shown increases the likelihood that brand campaign efforts – content and link posting – will see fruition via higher click through rates. This data indicates the best times of the day (EST) to focus for three big Social Media platforms:

  •     Twitter – Most active between 1 and 3pm Monday through Thursday. Least active after 8pm (Monday to Thursday) and anytime after Friday 3pm until Monday morning.
  •     Facebook – Most active between 1 and 4pm with a peak on Wednesdays at 3pm. Least active after 8pm and on the weekends.
  •     Tumblr – This popular blogging site shows dramatically different results. Tumblr is most active after 4pm, especially at 7pm, with a weekly peak on Friday evening.

The implications are clear and businesses should pay close attention to these statistics when allocating hours towards their Social Media marketing, while still recognizing the uniqueness of their own business. Marcus Maraih, Social Media Manager of Standard Marketing Ltd, weighs in “We definitely encourage our clients to concentrate significant efforts during the prescribed times but to be mindful of the characteristics of their customer base. It is advised that every business recognize their customer demographics and perform their own industry specific research before following broad generalizations.” Every major Social Media platform has analytics available that will show brands the activity of their consumer following.

Businesses unsure of their capabilities in Social Media Marketing or who cannot schedule efforts to accommodate the most active user times are encouraged to contact a professional internet marketing company with experience in Social Media Marketing as soon as possible.

ABOUT Standard Marketing

Standard Marketing Ltd is a long established internet marketing and website design firm in Vancouver, Canada. We’ve been creating success in Vancouver and across North America since 1999 and have a long string of clients who’ve been with us for many years. We’ve developed expertise in all aspects of internet, website, and digital marketing. Some of our staff have been in marketing and advertising for over 30 years. We have an A+ rating with the Better Business Bureau. Please contact us now to increase the profitability of your Internet Marketing.

Social Networking Expert, Top Network Marketer, Internet Visionary

In a move that rocked the Network Marketing industry, EvolvHealth announced today that Chris Tinney has joined forces to promote the e84 Challenge: http://share84.com

Dallas, TX (PRWEB) May 10, 2012

EvolvHealth announced that Chris Tinney has joined forces with Evolv to promote the e84 Challenge (http://share84.com) on the Internet and social networks like Facebook, Linked-in, and many others.

In announcing his move, Tinney said, “EvolvHealth is the first to marry social networking and network marketing, thereby creating a unique and powerful way for people to build a strong income online, when they do things they’re already doing every day on websites like Facebook, Google+, Linked-in and others.”

Tinney has already launched a new online community for EvolvHealth designed to take advantage of the new EvolvHealth Applications, called the Bodhi Group (http://www.bodhian.net), and he and his leaders are now hosting private conference calls with Network Marketing Leaders looking to make money now using the simple, innovative social network marketing tools EvolvHealth provides.

Chris Tinney is renowned for being the architect and Founder of the social network which helped launch the #1 most successful independent film of all time on Amazon.com (“The Secret”) and for using leading edge internet strategies to break records in the Network Marketing Industry. The Social Network he created around “The Secret” went on to become the official online community for the movie, and his numerous websites, online communities and forums such as http://www.BestMLMBusiness.com have become trusted guides in the network marketing industry.

EvolvHealth Chairman and Co-Founder Trey White said, “We’re excited to welcome the talent and experience Chris Tinney brings to Evolv. We’re sharing the positive change of the e84 Challenge with 8.4 million people, which will ultimately help many millions of families around the world, and we’re excited to work in partnership with leaders like Chris Tinney and his team in achieving our mission.”

In explaining his move, Chris Tinney said, “EvolvHealth is destined to be the next giant in the Industry. The tools they’re already providing their distributors – for free – are quickly becoming the Gold Standard in the network marketing and direct sales industry. Evolv’s simple texting strategy for acquiring both consumers and business-builders, called “TEXT – SHARE – PARTY,” is unique in the industry and creating fast growth and strong incomes. All of this positions EvolvHealth as the market leader and company to watch. In short, what they have done is make success achievable for anyone with a cell phone or a Facebook account.”

“For the past few years the network marketing industry has struggled to keep pace with the changing landscape. EvolvHealth is the first to recognize those changes and capitalize on them by providing distributors easy-to-use Facebook and cell phone applications – for free. Other companies such as MonaVie, Visalus, Organo Gold, NuSkin, Herbalife, and ForeverGreen will have to follow Evolv’s lead, or risk being left behind.”

“EvolvHealth is experiencing hyper growth because of a lot of factors, but one of the top reasons is the Evolv Compensation Plan that pays the new Distributor early and often, and their unique Customer Program allowing consumers the ability to enjoy free products by referring only 3 others. Everyone loves ‘free stuff,’ and EvolvHealth has given their Members a powerful program to capitalize on that fact.”

“I’m privileged to work with Top EvolvHealth Distributors, Sylvia and Garrett McGrath, and a corporate team that enjoys a successful, proven track record. As an early mover in Social Marketing, EvolvHealth has positioned itself to break industry records.”

Asked what his personal e84 Challenge was, Tinney said he is doing 84 days of random acts of kindness. This came as no surprise, as Chris and his wife Tysha are also the Founders of Spread Peace USA (http://www.spreadpeaceusa.org), a non-profit that has served more than 75,000 meals to the homeless and those in need. Chris and Tysha are excited to expand their charity’s outreach by joining forces with EvolvHealth.


EvolvHealth is a health movement company that has set an initial goal to help 8.4 million people to realize their health, fitness, wellness and life goals by completing their own e84 Challenge. The e84 Challenge is powered by 4 core categories to creating better health: Nutrition, Exercise, Energy and Support. Evolv’s exclusive line of products and technologies are backed by science and proven results, and the e84 is supported by a one-of-a-kind Facebook App that helps Challengers stick to their e84 in a fun, social media format to reach their goals. Headquartered in Dallas, Texas, Evolv products and the e84 is marketed through a network of independent business owners in the United States, Canada, Mexico, Chile, Colombia, and Peru. Please visit http://evolvhealthguy.myevolv.com for more information about EvolvHealth.

BioTime Announces First Quarter 2012 Financial Results and Recent Corporate

Alameda, Calif., May 10, 2012 – BioTime, Inc. (NYSE Amex: BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today reported financial results for the first quarter ended March 31, 2012 and highlighted recent corporate accomplishments.

Financial Results

Net Loss

Net loss attributable to BioTime, Inc. for the first quarter of 2012 was $5.0 million or $0.10 per share, compared to a net loss of $3.4 million or $0.07 per share for the same period of 2011.


Total revenue (including royalties from product sales and other revenue, revenue recognition of deferred license fees and grant income), on a consolidated basis, was $0.6 million in the first quarter of 2012, down $0.2 million from $0.8 million for the same period of 2011.  The decrease in revenue year-over-year in the first quarter 2012 is primarily attributable to a decrease in royalties and license fees from the sale of Hextend, BioTime’s proprietary blood plasma volume expander used in surgery and trauma care.  In addition, revenue from research products were adjusted downward to reflect a deferral of income as requested by a large pharmaceutical company partner.


Total expense for the first quarter of 2012 was $6.5 million, compared to a total expense of $4.9 million for the first quarter 2011.  Operating expenses increased $1.6 million year-over-year in the first quarter 2011 due to increased expenses related to the amortization of patent assets from our previous acquisitions, employee compensation and headcount-related costs, patent-related legal fees, and expenses related to our increased efforts in the ReneviaTM (formerly HyStem-Rx) clinical development program slated for human clinical trials this year and the PanC-DxTM diagnostic development program.

Cash Flow

Net cash used in operating activities was $5.7 million for the three months ended March 31, 2012 compared to $3.4 million for the three months ended March 31, 2011, reflecting the hiring of additional staff and increased headcount-related expenses, the payout of annual bonuses, and increased expense related to research and development programs in BioTime’s subsidiaries.  Excluding one-time discretionary expenses, which included bonuses and license payments, the net cash used in operations for the three months ended March 31, 2012 was approximately $4.2 million.

Balance Sheet

Cash and cash equivalents, on a consolidated basis, totaled $16.5 million as of March 31, 2011, compared with $22.2 million as of December 31, 2011.  A BioTime subsidiary, OncoCyte Corporation, currently holds 1,286,174 in BioTime common shares.  The common shares are accounted for as Treasury Stock on a consolidated basis, but this investment account, currently valued at approximately $5.0 million, is available to fund the operations of OncoCyte.

First Quarter and Recent Corporate Accomplishments

Advanced Near-Term Product Development

  • Provided an update on the development of ReneviaTM (formerly known as HyStem-Rx) including the product development milestones for the launch of ReneviaTM in Europe, the goal of obtaining the CE mark necessary for marketing ReneviaTM in European Union countries by year-end 2013, and the global distribution network marketing the HyStemline of research products being utilized in a wide array of medical research applications.

  • BioTime and its subsidiary OncoCyte Corporation provided an update on the development of PanC-DxTM, a novel diagnostic device to detect the presence of various human cancers, including cancers of the breast, lung, bladder, uterus, stomach, and colon, during routine check-ups.  Achieved several key advances, including: 1) the evaluation of over 50 potential cancer biomarkers discovered by OncoCyte and BioTime using antibody-based technology in blood samples from a proprietary sample bank derived from over 600 donors, including patients with cancers of the breast, colon, and pancreas, as well as healthy volunteers; and 2) the selection of seven such serum markers for monoclonal antibody production.

Expanded Revenue Opportunities

  • BioTime and its subsidiary LifeMap Sciences, Inc. announced a definitive agreement to acquire XenneX, Inc. through a merger of XenneX into LifeMap Sciences.  XenneX holds the exclusive, worldwide licenses to market GeneCardsand PanDaTox.  GeneCardsis a searchable, integrated database of human genes that provides concise genomic, transcriptomic, genetic, proteomic, functional and disease-related information, on all known and predicted human genes and generates revenue from customers worldwide, including biotechnology, pharmaceutical and other life sciences companies, as well as organizations dealing with biotechnology intellectual property.  PanDaTox is a recently developed, searchable, database that can be used to identify genes and intergenic regions that are unclonable in E. coli, to aid in the discovery of new antibiotics and biotechnologically beneficial functional genes, and to improve the efficiency of metabolic engineering.

  • Announced intent to transfer to LifeMap the products and technologies necessary to be the principal marketing subsidiary for BioTime research products, including ACTCellerateTM human progenitor cell lines, GMP human embryonic stem (hES) cell lines, hES cell lines carrying inherited genetic diseases, and ESpanTM growth media for progenitor cell lines for non-therapeutic uses.  LifeMap will utilize its databases as part of its online marketing strategy to reach life sciences researchers at biotech and pharmaceutical companies and at academic institutions and research hospitals worldwide.

  • Announced initiation of the manufacture of progenitors of muscle stem cells bearing hereditary diseases.  BioTime will produce the products from five hES cell lines from Reproductive Genetics Institute.  The muscle cell lines display the genes for Duchenne muscular dystrophy, Emery-Dreifuss muscular dystrophy, spinal muscular atrophy Type I, facioscapulohumeral muscular dystrophy 1A, and Becker muscular dystrophy.

Advanced RD Collaborations

  • Obtained an exclusive license from The Wistar Institute for technology related to a gene designated as SP100.  Wistar Institute researchers have demonstrated pivotal roles for this gene in both cancer and stem cell biology.  In conjunction with the license agreement, BioTime agreed to fund research at The Wistar Institute to advance the technology, and will receive certain rights to negotiate additional licenses for any technologies invented as a result of the research.

Expanded Board of Directors Involvement

  • Announced the formation of a Science Technology Committee of the BioTime Board of Directors to oversee the development and commercialization of BioTime’s technology and products in regenerative medicine and oncology.  The committee will regularly report to the Board of Directors and make recommendations to the Board as to the priorities, direction, quality, and execution for BioTime’s technology and product development programs, as well as allocations of financial resources and potential acquisitions of new technology and products.  The committee is chaired by director Andrew C. von Eschenbach, M.D., the former Commissioner of the U.S. Food and Drug Administration and former Director of the National Cancer Institute.

Key Research Publications and Presentations

  • BioTime and its subsidiaries presented updates on their operations, objectives, recent developments and strategies at a BioTime sponsored Investor Day in New York City on April 23, 2012.  Presentations as well as videos of the event are available for viewing on BioTime’s website at www.biotimeinc.com.

  • Published in the peer-reviewed journal Regenerative Medicine a paper detailing a study which characterizes a progenitor cell line produced from hES cells using proprietary ACTCellerateTMtechnology and demonstrating a scalable source of highly purified and identified progenitor cells capable of making definitive (non-hypertrophic) cartilage.  The study reports that the cells are capable of regenerating cartilage with long sought-after markers indicating the cells may be useful in the treatment of osteoarthritis currently afflicting over 26 million people in the United States.  The study also shows that the cells can be directly expanded on a scale needed for industrial manufacture, which will be necessary in order to make transplantable cells available in commercial quantities.

  • Presented at the following scientific and investor meetings: 7th Annual New York Stem Cell Summit; ROTH 24th Annual Growth Stock Conference2012 Maxim Group Growth Conference8th GTC Stem Cell Summit 2012; and the BioCentury Future Leaders in the Biotech Industry Conference.

About BioTime, Inc.

BioTime, headquartered in Alameda, California, is a biotechnology company focused on regenerative medicine and blood plasma volume expanders.  Its broad platform of stem cell technologies is developed through subsidiaries focused on specific fields of applications. BioTime develops and markets research products in the field of stem cells and regenerative medicine, including a wide array of proprietary ACTCellerate(TM) cell lines, HyStemhydrogels, culture media, and differentiation kits.  BioTime is developing Renevia(TM) (formerly known as HyStemRx), a biocompatible, implantable hyaluronan and collagen-based matrix for cell delivery in human clinical applications.  As an injectable product, Renevia(TM) may address an immediate need in cosmetic and reconstructive surgeries and other procedures by improving the process of transplanting adipose derived cells, mesenchymal stem cells, or other adult stem cells.  BioTime’s wholly owned subsidiary ES Cell International Pte. Ltd. has produced clinical-grade human embryonic stem cell lines that were derived following principles of Good Manufacturing Practice and currently offers them for use in research.  BioTime’s therapeutic product development strategy is pursued through subsidiaries that focus on specific organ systems and related diseases for which there is a high unmet medical need.  BioTime’s majority owned subsidiary Cell Cure Neurosciences, Ltd. is developing therapeutic products derived from stem cells for the treatment of retinal and neural degenerative diseases.  Cell Cure’s minority shareholder Teva Pharmaceutical Industries has an option to clinically develop and commercialize Cell Cure’s OpRegen(TM) retinal cell product for use in the treatment of age-related macular degeneration. BioTime’s subsidiary OrthoCyte Corporation is developing therapeutic applications of stem cells to treat orthopedic diseases and injuries.  Another subsidiary, OncoCyte Corporation, focuses on the diagnostic and therapeutic applications of stem cell technology in cancer, including the diagnostic product PanC-DxTM currently being developed for the detection of cancer in blood samples, and therapeutic strategies using vascular progenitor cells engineered to destroy malignant tumors.  ReCyte Therapeutics, Inc. is developing applications of BioTime’s proprietary induced pluripotent stem cell technology to reverse the developmental aging of human cells to treat cardiovascular and blood cell diseases.  BioTime’s newest subsidiary, LifeMap Sciences, Inc., is developing an online database of the complex cell lineages arising from stem cells to guide basic research and to market BioTime’s research products.  In addition to its stem cell products, BioTime develops blood plasma volume expanders, blood replacement solutions for hypothermic (low temperature) surgery, and technology for use in surgery, emergency trauma treatment and other applications. BioTime’s lead product, Hextend, is a blood plasma volume expander manufactured and distributed in the U.S. by Hospira, Inc. and in South Korea by CJ CheilJedang Corp. under exclusive licensing agreements.  Additional information about BioTime, ReCyte Therapeutics, Cell Cure, OrthoCyte, OncoCyte, BioTime Asia, LifeMap Sciences, and ESI can be found on the web at www.biotimeinc.com.

Forward-Looking Statements

Statements pertaining to future financial and/or operating results, future growth in research, technology, clinical development, and potential opportunities for BioTime and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements.  Any statements that are not historical fact (including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates”) should also be considered to be forward-looking statements.  Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty in the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights.  Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime and its subsidiaries, particularly those mentioned in the cautionary statements found in BioTime’s Securities and Exchange Commission filings.  BioTime disclaims any intent or obligation to update these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the following link to join our email alert list: http://phx.corporate-ir.net/phoenix.zhtml?c=83805p=irol-alerts


BioTime, Inc.
Peter Garcia
Chief Financial Officer
510-521-3390, ext 367


Judith Segall
510-521-3390, ext 301



March 31, 2012

December 31,

(unaudited) 2011


Cash and cash equivalents




Prepaid expenses and other current assets


Total current assets



Equipment, net


Deferred license and consulting fees




Intangible assets, net







Accounts payable and accrued liabilities


Deferred grant income


Deferred license revenue, current portion


Total current liabilities




Deferred license revenue, net of current portion


Deferred rent, net of current portion


Other long-term liabilities


Total long-term liabilities



Commitments and contingencies


Preferred Shares, no par value, 
authorized 1,000,000 shares; none issued

Common shares, no par value, 
authorized 75,000,000 shares; 50,321,962 issued, 
and 49,035,788 outstanding at March 31, 2012 
and at December 31, 2011


Contributed capital



Accumulated other comprehensive income


Accumulated deficit


Treasury stock at cost: 1,286,174 shares at 
March 31, 2012 and at December 31, 2011



    Total shareholders’ equity


Noncontrolling interest


Total equity





This announcement is distributed by Thomson Reuters on behalf of Thomson Reuters clients.

The owner of this announcement warrants that:
(i) the releases contained herein are protected by copyright and other applicable laws; and
(ii) they are solely responsible for the content, accuracy and originality of the
information contained therein.


Looking Younger With Smoother, Tighter Skin & Lighter Blemishes Is Easier

Younger looks through tighter and firmer skin is not the type of delivery one might expect coming in a package shipped by Amazon.Com. But Liberty Health Network, LLC (LHN) announces that effective immediately, the Beau Visage Facelift Mask can be ordered through Amazon’s fulfillment program.

Tampa, FL (PRWEB) May 04, 2012

As facial skin product sales continue their meteoric rise, Liberty Health Network announced that to meet the huge increase in demand, certain orders of the Beau Visage Facelift Without Surgery product will be inventoried and delivered through the Amazon Fulfillment By Amazon (FBA) program.

LHN’s Best Selling Aloe-Based Non Surgical Face Lift Mask is the first product to be introduced outside of the company’s affiliate and Network Marketing channels, The facial creme that is guaranteed to make the buyer look five or more years younger with results seen on TV’s Fox 13 Memphis is also the first LHN product in the Amazon fulfillment channel.

“The FBA program provides many benefits for our customers.” Say’s LHN Chief Financial Officer Tracy Grevert. “Through FBA, certain product buyers can obtain the single most requested feature – Free Shipping. In addition, Amazon’s customer interface is second to none, allowing our customers an unparallelled fulfillment experience. And because the program is so scalable, we are able to ensure that products are always available for our customers,” Grevert said.

“When customers see the Amazon logo, their comfort level goes up. When the customers see that Amazon is handling the entire sales and delivery process, confidence goes through the roof. Early indications are showing that Amazon sales with FBA are working hand-in-hand to increase sales. To say we’re excited is an understatement!” exclaimed LHN Chief Operating Officer Russell Bly.

Liberty’s Non Surgical Face Lift Mask is the only product currently in the FBA channel. LHN plans on adding more products to the FBA channel, as well as using FBA to augment the company’s distribution of products though other sales channels during peak periods.

About Liberty Health Network, LLC

Liberty Health Network is one of the nation’s leading Direct and Internet Marketing companies with a state-of-the-art Global Distribution facility in Tampa Bay, Fl. For 12 Years, the Liberty Health Network name has been synonymous with high quality Mortechem-Free Nutritional Supplements, Anti Aging Skin Care, and Internet Web Applications. The statements made on this website have not been evaluated by the Food Drug Administration. These products are not intended to diagnose, prevent, treat, or cure any disease.

Businesses or Individuals interested in distributing Liberty Products or requiring more information on this topic should contact Chief Operating Officer Russell Bly at (813) 774-8191 or e-mail at office(at)libertyhealthbiz(dot)com.